CEP-37440 TRIHYDROCHLORIDE DIHYDRATE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H38ClN7O3.3ClH.2H2O
Molecular Weight	725.534
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CEP-37440 TRIHYDROCHLORIDE DIHYDRATE

Structure Search

SMILES

O.O.Cl.Cl.Cl.CNC(=O)C1=C(NC2=NC(NC3=CC=C4C[C@H](CCCC4=C3OC)N5CCN(CCO)CC5)=NC=C2Cl)C=CC=C1

InChI

InChIKey=RDIKDYVDRWYSQX-DHOIFHORSA-N

InChI=1S/C30H38ClN7O3.3ClH.2H2O/c1-32-29(40)23-7-3-4-9-25(23)34-28-24(31)19-33-30(36-28)35-26-11-10-20-18-21(6-5-8-22(20)27(26)41-2)38-14-12-37(13-15-38)16-17-39;;;;;/h3-4,7,9-11,19,21,39H,5-6,8,12-18H2,1-2H3,(H,32,40)(H2,33,34,35,36);3*1H;2*1H2/t21-;;;;;/m0...../s1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C30H38ClN7O3
Molecular Weight	580.121
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/27009091 | https://www.ncbi.nlm.nih.gov/pubmed/26753004

CEP-37440 is a potent ATP-competitive, highly kinase selective, and orally active inhibitor of FAK1 and anaplastic lymphoma kinase (ALK). In addition to a favorable metabolic stability and pharmacokinetic profile preclinically, CEP-37440 is also a brain penetrant. CEP-37440 was able to inhibit the proliferation of certain IBC cells by decreasing the levels of phospho-FAK1 (Tyr 397); none of the cells expressed ALK. Studies using IBC xenograft models showed that CEP-37440 also effectively reduces the growth of the primary tumor xenografts and inhibits the development of brain metastases in mice.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Focal adhesion kinase 1 15 Target ID: CHEMBL2695 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804	Inhibitor 8297		2.0 nM [IC50]
ALK tyrosine kinase receptor 25 Target ID: CHEMBL4247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804 \| https://www.ncbi.nlm.nih.gov/pubmed/27009091	Inhibitor 8297		3.1 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Solid tumors 145 Sources: https://clinicaltrials.gov/ct2/show/NCT01922752	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1533 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CEP-37440 plasma	Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1612 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CEP-37440 plasma	Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
16429 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804	10 mg/kg single, oral dose: 10 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		CEP-37440 plasma	Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27527804	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		CEP-37440 plasma	Mus musculus population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P009CR5	https://www.1pchem.com/search?query=1P009CR5
ApexBio Technology	B3271	https://www.apexbt.com/catalogsearch/result/?q=B3271
AstaTech	F13321	http://astatechinc.com/CPSResult.php?CRNO=F13321
Cayman Chemical	21278	http://www.caymanchem.com/app/template/Product.vm/catalog/21278
Chem Scene	CS-2684	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-2684
ChemShuttle	157280	https://www.chemshuttle.com/catalogsearch/result/?q=157280
Combi-Blocks	QV-7347	http://www.combi-blocks.com/cgi-bin/find.cgi?QV-7347
Excenen	EX-A1543	http://www.excenen.com/searchresultlist.php?id=EX-A1543
Excenen	EX-A1625	http://www.excenen.com/searchresultlist.php?id=EX-A1625
MedChem Express	HY-15841	https://www.medchemexpress.com/search.html?q=HY-15841&ft=&fa=&fp=
MolPort	MolPort-042-676-269	https://www.molport.com/shop/molecule-link/MolPort-042-676-269
MolPort	MolPort-044-561-845	https://www.molport.com/shop/molecule-link/MolPort-044-561-845
Molnova	M17273	https://www.molnova.com/en/serch-list.html?keywords=M17273
MuseChem	I001499	https://www.musechem.com/product/I001499.html
TargetMol	T2655	https://www.targetmol.com/search?keyword=T2655
eMolecules	108759164	https://orderbb.emolecules.com/search/#?query=108759164
eMolecules	301191637	https://orderbb.emolecules.com/search/#?query=301191637
eMolecules	50282356	https://orderbb.emolecules.com/search/#?query=50282356
mcule	MCULE-3401000639	https://mcule.com/MCULE-3401000639/
mcule	MCULE-8370728429	https://mcule.com/MCULE-8370728429/

PubMed

Title	Date	PubMed
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	2014 Jul	25322323
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).	2016 Aug 25	27527804

Patents

Sample Use Guides

In Vivo Use Guide

CEP-37440 supplied as 25 mg and 100 mg capsules and orally administered daily.

Route of Administration: Oral

In Vitro Use Guide

CEP-37440 was screened against both NPM-ALK+ ALCL cell lines (Sup-M2 and Karpas-299) and NPM-ALK− hematologic cell lines (Hut-102 and K562) and demonstrated selective cytotoxicity in the oncogene-addicted cell lines in nanomolar range

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:55:07 GMT 2023` Edited by `admin` on `Sat Dec 16 05:55:07 GMT 2023`
Record UNII	2N1592JH39
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEP-37440 TRIHYDROCHLORIDE DIHYDRATE

Code

English

BENZAMIDE, 2-((5-CHLORO-2-(((6S)-6,7,8,9-TETRAHYDRO-6-(4-(2-HYDROXYETHYL)-1-PIPERAZINYL)-1-METHOXY-5H-BENZOCYCLOHEPTEN-2-YL)AMINO)-4-PYRIMIDINYL)AMINO)-N-METHYL-, HYDROCHLORIDE, HYDRATE (1:3:2)

Systematic Name

English

Code System Code Type Description

FDA UNII

2N1592JH39

Created by admin on Sat Dec 16 05:55:07 GMT 2023 , Edited by admin on Sat Dec 16 05:55:07 GMT 2023

PRIMARY

PUBCHEM

71721647

Created by admin on Sat Dec 16 05:55:07 GMT 2023 , Edited by admin on Sat Dec 16 05:55:07 GMT 2023

PRIMARY

CAS

1391712-75-6

Created by admin on Sat Dec 16 05:55:07 GMT 2023 , Edited by admin on Sat Dec 16 05:55:07 GMT 2023

PRIMARY

Related Record Type Details


					O3MNS8782H

CEP-37440

PARENT -> SALT/SOLVATE

Related Record Type Details


					O3MNS8782H

CEP-37440

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27527804Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/27009091 | https://www.ncbi.nlm.nih.gov/pubmed/26753004

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27527804
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/27009091 | https://www.ncbi.nlm.nih.gov/pubmed/26753004

C_max

T_1/2